Opus Genetics receives FDA incentive for retinal gene therapy
Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration for one of its potential therapies. The Research Triangle …